参考文献/References:
[1] Borlaug BA. Evaluation and management of heart failure with preserved ejection fraction[J]. Nat Rev Cardiol,2020,17(9):559-573.[2] Kittleson MM,Panjrath GS,Amancherla K,et al. 2023 ACC Expert Consensus decision pathway on management of heart failure with preserved ejection fraction:a report of the American College of Cardiology Solution Set Oversight Committee[J]. J Am Coll Cardiol,2023,81(18):1835-1878.[3] Teuber JP,Essandoh K,Hummel SL,et al. NADPH oxidases in diastolic dysfunction and heart failure with preserved ejection fraction[J]. Antioxidants (Basel),2022,11(9):1822.[4] Budde H,Hassoun R,Mugge A,et al. Current understanding of molecular pathophysiology of heart failure with preserved ejection fraction[J]. Front Physiol,2022,13:928232.[5] Liang BR,Zhou Z,Yang ZQ,et al. AGEs-RAGE axis mediates myocardial fibrosis via activation of cardiac fibroblasts induced by autophagy in heart failure[J]. Exp Physiol,2022,107(8):879-891.[6] Rush CJ,Berry C,Oldroyd KG,et al. Prevalence of coronary artery disease and coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction[J]. JAMA Cardiol,2021,6(10):1130-1143.[7] Simmonds SJ,Cuijpers I,Heymans S,et al. Cellular and molecular differences between HFpEF and HFrEF:a step ahead in an improved pathological understanding[J]. Cells,2020,9(1):242.[8] Schiattarella GG,Rodolico D,Hill JA. Metabolic inflammation in heart failure with preserved ejection fraction[J]. Cardiovasc Res,2021,117(2):423-434.[9] Capone F,Sotomayor-Flores C,Bode D,et al. Cardiac metabolism in HFpEF:from fuel to signalling[J]. Cardiovasc Res,2023,118(18):3556-3575.[10] Challa AA,Lewandowski ED. Short-chain carbon sources:exploiting pleiotropic effects for heart failure therapy[J]. JACC Basic Transl Sci,2022,7(7):730-742.[11] Son TK,Toan NH,Thang N,et al. Prediabetes and insulin resistance in a population of patients with heart failure and reduced or preserved ejection fraction but without diabetes,overweight or hypertension[J]. Cardiovasc Diabetol,2022,21(1):75.[12] Verhaert DVM,Brunner-La Rocca HP,van Veldhuisen DJ,et al. The bidirectional interaction between atrial fibrillation and heart failure:consequences for the management of both diseases[J]. Europace,2021,23(23 suppl 2):ii40-ii45.[13] Mone P,Lombardi A,Kansakar U,et al. Empagliflozin improves the microRNA signature of endothelial dysfunction in patients with HFpEF and diabetes[J]. J Pharmacol Exp Ther,2023,384(1):116-122.[14] Defronzo RA,Reeves WB,Awad AS. Pathophysiology of diabetic kidney disease:impact of SGLT2 inhibitors[J]. Nat Rev Nephrol,2021,17(5):319-334.[15] Lewis GA,Dodd S,Clayton D,et al. Pirfenidone in heart failure with preserved ejection fraction:a randomized phase 2 trial[J]. Nat Med,2021,27(8):1477-1482.[16] Deng Y,Xie M,Li Q,et al. Targeting mitochondria-inflammation circuit by beta-hydroxybutyrate mitigates HFpEF[J]. Circ Res,2021,128(2):232-245.[17] Hatahet J,Cook TM,Bonomo RR,et al. Fecal microbiome transplantation and tributyrin improves early cardiac dysfunction and modifies the BCAA metabolic pathway in a diet induced pre-HFpEF mouse model[J]. Front Cardiovasc Med,2023,10:1105581.[18] Zhang L,Chen J,Yan L,et al. Resveratrol ameliorates cardiac remodeling in a murine model of heart failure with preserved ejection fraction[J]. Front Pharmacol,2021,12:646240.[19]李兵达. Adropin在射血分数保留型心衰中的作用及机制[D].江西:南昌大学,2022.[20] Shah SJ,Borlaug BA,Chung ES,et al. Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF Ⅱ):a randomised,multicentre,blinded,sham-controlled trial[J]. Lancet,2022,399(10330):1130-1140.[21] Schnelle M,Leha A,Eidizadeh A,et al. Plasma biomarker profiling in heart failure patients with preserved ejection fraction before and after spironolactone treatment:results from the Aldo-DHF trial[J]. Cells,2021,10(10):2796.[22] Jackson AM,Jhund PS,Anand IS,et al. Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction[J]. Eur Heart J,2021,42(36):3741-3752.[23] Ledwidge M,Dodd JD,Ryan F,et al. Effect of sacubitril/valsartan vs valsartan on left atrial volume in patients with pre-heart failure with preserved ejection fraction:the PARABLE randomized clinical trial[J]. JAMA Cardiol,2023,8(4):366-375.[24] Patel K,Fonarow GC,Ahmed M,et al. Calcium channel blockers and outcomes in older patients with heart failure and preserved ejection fraction[J]. Circ Heart Fail,2014,7(6):945-952.[25] Wang X,Ju J,Chen Z,et al. Associations between calcium channel blocker therapy and mortality in heart failure with preserved ejection fraction[J]. Eur J Prev Cardiol,2022,29(9):1343-1351.[26] Jarrar YB,Jarrar Q,Abaalkhail SJ,et al. Molecular toxicological alterations in the mouse hearts induced by sub-chronic thiazolidinedione drugs administration[J]. Fundam Clin Pharmacol,2022,36(1):143-149.[27] Liu J,Hu X. Impact of insulin therapy on outcomes of diabetic patients with heart failure:a systematic review and meta-analysis[J]. Diab Vasc Dis Res,2022,19(3):14791641221093175.[28] Li J,Minczuk K,Massey JC,et al. Metformin improves cardiac metabolism and function,and prevents left ventricular hypertrophy in spontaneously hypertensive rats[J]. J Am Heart Assoc,2020,9(7):e015154.[29] Dia M,Leon C,Chanon S,et al. Effect of metformin on T2D-induced MAM Ca2+ uncoupling and contractile dysfunction in an early mouse model of diabetic HFpEF[J]. Int J Mol Sci,2022,23(7):3569.[30] Voros I,Onodi ZS,Toth VE,et al. Investigation of cardiotoxicity by dipeptidyl-peptidase-4 inhibitors in a human cardiomyocyte cell line as well as in samples from chronic heart failure patients[J]. Cardiovasc Res,2022,118(suppl 1):1.[31] Mu L,Wang Z,Ren J,et al. Impact of DPP-4 inhibitors on plasma levels of BNP and NT-pro-BNP in type 2 diabetes mellitus[J]. Diabetol Metab Syndr,2022,14(1):30.[32] Zakaria EM,Tawfeek WM,Hassanin MH,et al. Cardiovascular protection by DPP-4 inhibitors in preclinical studies:an updated review of molecular mechanisms[J]. Naunyn Schmiedebergs Arch Pharmacol,2022,395(11):1357-1372.[33] Withaar C,Meems LMG,Markousis-Mavrogenis G,et al. The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction[J]. Cardiovasc Res,2021,117(9):2108-2124.[34] Filippatos G,Butler J,Farmakis D,et al. Empagliflozin for heart failure with preserved left ventricular ejection fraction with and without diabetes[J]. Circulation,2022,146(9):676-686.[35]黄鑫涛,白保强,李之恒,等. 不同剂量瑞舒伐他汀对老年高血压并射血分数保留型慢性心力衰竭患者心室重构的影响[J]. 重庆医科大学学报,2022,47(1):66-73.[36] Park JJ,Yoon M,Cho HW,et al. C-reactive protein and statins in heart failure with reduced and preserved ejection fraction[J]. Front Cardiovasc Med,2022,9:1064967.[37] Zelniker TA,Bonaca MP,Furtado RHM,et al. Effect of dapagliflozin on atrial fibrillation in patients with type 2 diabetes mellitus:insights from the DECLARE-TIMI 58 trial[J]. Circulation,2020,141(15):1227-1234.[38] Li LY,Lou Q,Liu GZ,et al. Sacubitril/valsartan attenuates atrial electrical and structural remodelling in a rabbit model of atrial fibrillation[J]. Eur J Pharmacol,2020,881:173120.[39] Zhu X,Wu Y,Ning Z. Meta-analysis of catheter ablation versus medical therapy for heart failure complicated with atrial fibrillation[J]. Cardiol Res Pract,2021,2021:7245390.[40] Gu MJ,Hyon JY,Lee HW,et al. Glycolaldehyde,an advanced glycation end products precursor,induces apoptosis via ROS-mediated mitochondrial dysfunction in renal mesangial cells[J]. Antioxidants (Basel),2022,11(5):934.[41] Senatus L,Maclean M,Arivazhagan L,et al. Inflammation meets metabolism:roles for the receptor for advanced glycation end products axis in cardiovascular disease[J]. Immunometabolism,2021,3(3):e210024.[42] Sun J,Xu J,Yang Q. Expression and predictive value of NLRP3 in patients with atrial fibrillation and stroke[J]. Am J Transl Res,2022,14(5):3104-3112.[43] Wang S,Zhang J,Wang Y,et al. NLRP3 inflammasome as a novel therapeutic target for heart failure[J]. Anatol J Cardiol,2022,26(1):15-22.
相似文献/References:
[1]孙刚,黄冠华,综述.高血压合并心力衰竭的治疗策略[J].心血管病学进展,2016,(2):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
SUN Gang,HUANG Guanhua.Treatment Strategy of Hypertension with Heart Failure[J].Advances in Cardiovascular Diseases,2016,(2):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
[2]范贵娟,综述,徐瑞,等.盐敏感性高血压的研究进展[J].心血管病学进展,2016,(4):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
FAN Guijuan,XU Rui.Research Progress of Salt Sensitive Hypertension[J].Advances in Cardiovascular Diseases,2016,(2):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
[3]陈源源.钙通道阻滞剂在降压治疗中的应用[J].心血管病学进展,2015,(6):662.[doi:10.3969/j.issn.1004-3934.2015.06.002]
CHEN Yuanyuan.Application of Calcium Channel Blockers in Hypertension Treatment[J].Advances in Cardiovascular Diseases,2015,(2):662.[doi:10.3969/j.issn.1004-3934.2015.06.002]
[4]张瑞 毛露 孙硕 Dirk Hermann 陈艾东.内皮素-1干预成为高血压治疗新靶点的展望[J].心血管病学进展,2019,(7):969.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.000]
ZHANG Rui MAO LuSUN ShuoDIRK Hermann CHEN Aidong.The Prospect of Endothelin-1 Intervention as A New Target for the Treatment of Hypertension[J].Advances in Cardiovascular Diseases,2019,(2):969.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.000]
[5]张毅,柳志红.动态血压监测在高血压中的应用现状与问题[J].心血管病学进展,2019,(6):848.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.003]
ZHANG Yi,LIU Zhihong.Current status and nsolved Pproblems of Ambulatory Blood Pressure Monitoring for the Management of Hypertension[J].Advances in Cardiovascular Diseases,2019,(2):848.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.003]
[6]黄秋瑾 胡蓉.高血压合并糖尿病患者血压控制率和控制目标的探讨[J].心血管病学进展,2019,(7):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
HUANG QiujinHU Rong.Discussion on Blood Pressure Control Rate and Control Target in Patients with Hypertension Complicated with Diabetes[J].Advances in Cardiovascular Diseases,2019,(2):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
[7]张旭明 王曦.高血压对认知功能的影响[J].心血管病学进展,2019,(7):977.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.003]
ZHANG Xuming,WANG Xi.The Relationship Between Hypertension and Cognitive Function[J].Advances in Cardiovascular Diseases,2019,(2):977.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.003]
[8]凌梦军 陈明凌梦军.阻塞性睡眠呼吸暂停低通气综合征与高血压关系的研究进展[J].心血管病学进展,2019,(5):722.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.015]
[9]李波 郭毅 田进文 邓珏琳.高血压合并2型糖尿病的治疗进展[J].心血管病学进展,2019,(9):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
LI Bo,GUO Yi,TIAN Jinwen,et al.Therapy in Hypertensive Patients with Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2019,(2):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
[10]王继航 赵施皓 李开亮 田进文 李玉龙 付士辉 沈明志 邓珏琳.远程医疗在高血压病管理中的研究进展[J].心血管病学进展,2019,(9):1199.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.003]
WANG Jihang,ZHAO Shihao,LI Kailiang,et al.Telemedicine in Hypertension Management[J].Advances in Cardiovascular Diseases,2019,(2):1199.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.003]
[11]高可 杨蕾 姚新叶 郑小璞.射血分数保留性心力衰竭动物模型的研究进展[J].心血管病学进展,2020,(8):834.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.013]
GAO Ke,YANG Lei,YAO Xinye,et al.Advances in Animal Models ofHeart Failure with Preserved Ejection Fraction[J].Advances in Cardiovascular Diseases,2020,(2):834.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.013]